Thus, all the international guidelines propose HCC surveillance programs in high-risk patients by using liver ultrasound (US) every 6 months, with or without the concurrent use of alpha-fetoprotein (AFP) [5,6,7]. The gene discussed is AFP; the disease is hepatocellular carcinoma.